CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 57 enrolled
Drug / intervention
Pazopanibdrug
Likely dose
Pazopanib 800 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00731211
NCT00731211Phase 2Completed
CompareCT.gov

A Phase II Trial of Pazopanib in Patients With Metastatic Renal Cell Carcinoma Previously Treated With Sunitinib or Bevacizumab

SCRI Development Innovations, LLC·interventional·Posted Aug 8, 2008·Updated May 20, 2015

In Brief

A Phase 2 clinical trial evaluating Pazopanib for Renal Cell Carcinoma. Completed, enrolled 57 participants across 17 sites.

Detailed Summary

This is a Phase II, non-randomized, open-label, single-arm study in patients with metastatic renal cell carcinoma who have received one prior targeted therapy with either sunitinib or bevacizumab. The planned enrollment for this study is 60 patients.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRenal Cell Carcinoma
CountriesUnited States
CollaboratorsGlaxoSmithKline

Timeline

Phase 2CompletedFinished
2009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 8, 2008
Enrollment StartSep 1, 2008
Primary CompletionMay 1, 2011
Study CompletionSep 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 17.9 years ago

Interventions

Pazopanibdrug

800 mg of pazopanib orally each day continuously